Familial Pancreatic Cancer Increases Risk

A new study has shown that a person who has multiple family members with pancreatic cancer (familial pancreatic cancer) is six times as likely to develop that cancer.

According o the study, this risk is even higher, nine times that of the general population, if one of their relatives developed their cancer under the age of 50.

Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.

Young-onset cancer is a hallmark of many familial cancer syndromes, but it was not clear whether family members of young-onset familial pancreatic cancer patients were at greater risk than family members of older-onset patients.

For the study, Alison P. Klein, at Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins School of Medicine in Baltimore, and colleagues compared the observed incidence of pancreatic cancer in over 9,000 individuals from 1,718 families.

Standardized incidence ratios for familial pancreatic cancer and for sporadic pancreatic cancer were calculated with data from the National Familial Pancreas Tumor Registry and compared with those from the Surveillance, Epidemiology, and End Results database.

Use of Swedish 'snus' is Linked to a Doubled Risk of Pancreatic Cancer
People who use Swedish moist snuff (snus) run twice the risk of developing cancer of the pancreas.

The researchers found that relatives of familial pancreatic cancer patients had a more than six-fold higher incidence of pancreatic cancer than the general population. Those with relatives diagnosed before the age of 50 years had a more than ninefold higher incidence.

In contrast, individuals with just a single relative with pancreatic cancer were at twice the risk of pancreatic cancer whether or not the relative with pancreatic cancer was diagnosed before or after the age of 50.

Vaccine for Pancreatic Cancer Halts Progression of Disease in Some Patients
A dendritic cell-based therapeutic vaccine for pancreatic cancer developed has successfully stalled the disease from progressing in a handful of patients three years post-vaccination.

"These data should help to further inform risk assessment and subsequent early detection screening of individuals at high risk of developing pancreatic cancer," the authors said.

The study has been published online January 12 in the Journal of the National Cancer Institute.

Surgery and Adjuvant Therapy Can Work for Pancreatic Cancer
In a study researchers have shown that giving patients both radiation and chemotherapy after completely removing invasive pancreatic cancer may improve...

Source-ANI
TRI